SCI Abstract

search
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of M...
Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax
Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax
Acute lymphoblastic leukemia (ALL), with over 80% arising from B-cell lineage precursors (BCP-ALL), is the most common hem...
An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy
An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy
We investigated a novel SLAMF7-promoter driven oncolytic adenovirus (Ad[CE1A]) as a potential therapeutic for multiple mye...
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments
T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a high-risk hematological disease constituting ~20% of acute leukemias. To...
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management
Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes are a rare group of biologically and clin...
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML
Venetoclax plus azacitidine (VEN + AZA) is widely used in acute myeloid leukemia (AML). This study explored th...
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.A...
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia
The transcription factor MYB is frequently upregulated in T-cell acute lymphoblastic leukemia (T-ALL), a hematological mal...
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
The use of measurable residual disease (MRD) as a biomarker for prognostication, risk stratification, and therapeutic deci...
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive malignancy characterized by the aberrant accumulation of imma...
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset au...
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Kantarjian H, Jabbour E, Cortes J. Chronic Myeloid Leukemia. In: Loscalzo J, Fauci A, Kasper D, Hauser S, et al., editors....
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from un...
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial
The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. Th...
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive c...
Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights
In this issue, Mattano et al. report on the development of osteonecrosis among patients with acute lymphoblastic leukemia ...
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance
Relapse in T-cell acute lymphoblastic leukemia (T-ALL) may signify the persistence of leukemia-initiating cells (L-ICs). E...
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia
Infant and adult MLL1/KMT2A-rearranged (MLLr) leukemia represents a disease with a dismal prognosis. Here, we present a fu...
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is a malignancy with a poor prognosis. The expansion of leukemic cells is associated with the...
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
Credit: Courtesy of G. PizzoloLuigi Chieco Bianchi, called Gino by his friends, died in Padua on June 23rd 20...
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is still an incurable disease, with many patients developing resistance to conventional...
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Osteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In retrospective analyses, superior...
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol ...
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce COVID-19-related mortality. However, w...